School of Health and Related Research, University of Sheffield, Sheffield, UK.
Br J Surg. 2014 Aug;101(9):1040-52. doi: 10.1002/bjs.9566. Epub 2014 Jun 25.
A Health Technology Assessment was conducted to evaluate the relative clinical effectiveness and cost-effectiveness of minimally invasive techniques (foam sclerotherapy (FS), endovenous laser ablation (EVLA) and radiofrequency ablation (RFA)) for managing varicose veins, in comparison with traditional surgery.
A systematic review of randomized clinical trials (RCTs) was undertaken to assess the effectiveness of minimally invasive techniques compared with other treatments, principally surgical stripping, in terms of recurrence of varicose veins, Venous Clinical Severity Score (VCSS), pain and quality of life. Network meta-analysis and exploratory cost-effectiveness modelling were performed.
The literature search conducted in July 2011 identified 1453 unique citations: 31 RCTs (51 papers) satisfied the criteria for effectiveness review. Differences between treatments were negligible in terms of clinical outcomes, so the treatment with the lowest cost appears to be most cost-effective. Total FS costs were estimated to be lowest, and FS was marginally more effective than surgery. However, relative effectiveness was sensitive to the model time horizon. Threshold analysis indicated that EVLA and RFA might be considered cost-effective if their costs were similar to those for surgery. These findings are subject to various uncertainties, including the risk of bias present in the evidence base and variation in reported costs.
This assessment of currently available evidence suggests there is little to choose between surgery and the minimally invasive techniques in terms of efficacy or safety, so the relative cost of the treatments becomes one of the deciding factors. High-quality RCT evidence is needed to verify and further inform these findings.
为了评估微创技术(泡沫硬化疗法(FS)、静脉内激光消融术(EVLA)和射频消融术(RFA))与传统手术相比治疗静脉曲张的相对临床效果和成本效益,进行了一项健康技术评估。
系统地回顾了随机临床试验(RCTs),以评估微创技术与其他治疗方法(主要是手术剥脱术)相比在静脉曲张复发、静脉临床严重程度评分(VCSS)、疼痛和生活质量方面的效果。进行了网络荟萃分析和探索性成本效益建模。
2011 年 7 月进行的文献检索确定了 1453 个独特的引用:31 项 RCT(51 篇论文)符合有效性审查标准。治疗方法之间在临床结果方面差异很小,因此成本最低的治疗方法似乎最具成本效益。FS 的总成本估计最低,FS 比手术更有效。然而,相对有效性对模型时间范围敏感。阈值分析表明,如果 EVLA 和 RFA 的成本与手术相似,则可以考虑其具有成本效益。这些发现受到各种不确定性的影响,包括证据基础中的偏倚风险和报告成本的差异。
对现有证据的评估表明,在疗效或安全性方面,手术与微创技术之间几乎没有区别,因此治疗的相对成本成为决定因素之一。需要高质量的 RCT 证据来验证和进一步阐明这些发现。